ISPOR 2024 Home
Toggle navigation
About
News Center
Award Winners
Program
Program
Learning Formats
Plenary Sessions
Posters
Program Committee
Digital Conference Pass
Exhibits & Sponsorship
Sponsor List
Exhibitor Directory
Media Partners
Photo Gallery
ISPOR
2024
May 5-8, 2024
Home
Events
Past Conferences
ISPOR 2024
Program
Plenary Sessions
Session
Cost-Effectiveness of Tremelimumab Plus Durvalumab for the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma in the United States
May 8, 2024, 10:00 AM
«
381
382
383
384
385
386
387
388
389
390
(current)
»